Onlay Resorbable Biosynthetic Versus Underlay Biologic Mesh Ventral Hernia Repair in Contaminated Fields
Journal of Surgical Research · 2025-01 · 305 · 398-405
DOI: 10.1016/j.jss.2024.10.044 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Surgical Research, 2025-01. Verfasst von Chris Amro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plastic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania; Hansjörg Wyss Department of Plastic Surge…. Hauptthemen laut MEDLINE: Hernia, Ventral, Surgical Mesh, Herniorrhaphy, Surgical Wound Infection. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
INTRODUCTION: Abdominal wall reconstruction (AWR) with ventral hernia repair (VHR) in the setting of contamination poses unique and controversial challenges. The purpose of this study was to examine the efficacy of onlay resorbable biosynthetic mesh against underlay biologic mesh in contaminated VHR with AWR. METHODS: A single-center retrospective review from 2015 to 2021 was performed examining subjects who underwent VHR with AWR in contaminated fields (Centers for Disease Control wound class II-IV). A matched paired analysis based on age, body mass index, and Centers for Disease Control wound class was conducted among patients who utilized resorbable biosynthetic mesh in an onlay fashion and biologic mesh in an underlay fashion. RESULTS: A total of 94 patients (47 per group) underwent VHR with AWR in contaminated fields. Patients who utilized biosynthetic mesh had an average defect size of 314.56 ± 214.65 cm2, required component separation (57.4%), and were often recurrent (61.7%). Majority of contamination were clean-contaminated (68.1%), followed by dirty/infected (19.1%), and contaminated (12.8%). Patients utilizing resorbable biosynthetic mesh experienced fewer surgical site occurrences (SSOs) (46.8% versus 72.3%, P < 0.05) and fewer SSO procedural interventions (19.1% versus 38.4%, P < 0.05). Patients with biosynthetic mesh had fewer hernia recurrences compared to biologic mesh use; however, was not statistically significant (14.9% versus 30.4%, P = 0.07), with a mean follow-up of 25.73 ± 18.66 mo. CONCLUSIONS: Utilization of resorbable biosynthetic mesh may be preferable to biologic mesh in contaminated fields due to lower rates of SSOs and interventions, ultimately reducing the postoperative clinical and financial burden for this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Plastic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania; Hansjörg Wyss Department of Plastic Surgery, NYU Langone, New York, New York. Electronic address: chris.amro542…
- Division of Plastic Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania.
Förderung
- National Institutes of Health
Zitieren
APA
Amro, C., Ewing, J. N., Romeo, D. J., Rhodes, I. J., Gala, Z., Lemdani, M. S., McGraw, J. R., Broach, R. B., Kovach, S. J., & Fischer, J. P. (2025). Onlay Resorbable Biosynthetic Versus Underlay Biologic Mesh Ventral Hernia Repair in Contaminated Fields. Journal of Surgical Research, 305, 398-405. https://doi.org/10.1016/j.jss.2024.10.044
Vancouver
Amro C, Ewing JN, Romeo DJ, Rhodes IJ, Gala Z, Lemdani MS, et al. Onlay Resorbable Biosynthetic Versus Underlay Biologic Mesh Ventral Hernia Repair in Contaminated Fields. Journal of Surgical Research. 2025;305:398-405. doi:10.1016/j.jss.2024.10.044
BibTeX
@article{Amro2025,
author = {Amro, Chris and Ewing, Jane N and Romeo, Dominic J and Rhodes, Isaiah J and Gala, Zachary and Lemdani, Mehdi S and McGraw, J Reed and Broach, Robyn B and Kovach, Stephen J and Fischer, John P},
title = {Onlay Resorbable Biosynthetic Versus Underlay Biologic Mesh Ventral Hernia Repair in Contaminated Fields},
journal = {Journal of Surgical Research},
year = {2025},
volume = {305},
pages = {398--405},
doi = {10.1016/j.jss.2024.10.044}
}
EUVIMED